ストックスクリーナーアプリを入手
9.17
5.17%
-0.50
前日終値:
$9.67
開ける：
$9.9
24時間の取引高:
610.83K
Relative Volume:
0.40
時価総額：
$51.26M
収益：
-
当期純損益:
$-121.02M
株価収益率:
-0.8144
EPS:
-11.26
ネットキャッシュフロー:
$-114.09M
1週間 パフォーマンス:
-23.26%
1か月 パフォーマンス:
-61.62%
6か月 パフォーマンス:
-74.53%
1年 パフォーマンス:
-99.18%
1日の値動き範囲:
$9.02
$10.40
1週間の範囲:
$9.02
$11.95
52週間の値動き範囲:
$9.02
$1,244.80
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Company Profile
名前
Tonix Pharmaceuticals Holding Corp
セクター
電話
212-980-9155
住所
26 MAIN STREET, SUITE 101, CHATHAM, NY
TNXP を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TNXP
Tonix Pharmaceuticals Holding Corp
|
9.17 | 51.26M | 0 | -121.02M | -114.09M | -11.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2022-04-18 | 開始されました | Noble Capital Markets | Outperform |
| 2019-04-18 | アップグレード | ROTH Capital | Neutral → Buy |
| 2017-08-18 | アップグレード | ROTH Capital | Neutral → Buy |
| 2016-09-07 | ダウングレード | ROTH Capital | Buy → Neutral |
| 2016-02-17 | 繰り返されました | Oppenheimer | Outperform |
| 2015-11-04 | 開始されました | Cantor Fitzgerald | Buy |
| 2015-06-12 | 開始されました | Oppenheimer | Outperform |
| 2015-02-17 | 繰り返されました | ROTH Capital | Buy |
| 2014-09-29 | 繰り返されました | ROTH Capital | Buy |
すべてを表示
Tonix Pharmaceuticals Holding Corp (TNXP) 最新ニュース
(TNXP) On The My Stocks Page - Stock Traders Daily
Tonix Pharmaceuticals appoints new CTO amid drug development - MSN
Tonix Pharmaceuticals reports positive phase 1 results for TNX-1500, advancing to Phase 2 - Proactive Investors USA
Tonix Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Highlights - ADVFN
Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Gap DownHere's Why - MarketBeat
Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Gap UpWhat's Next? - MarketBeat
Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Up 13.2%Should You Buy? - MarketBeat
Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Down 12.6%Time to Sell? - MarketBeat
Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Down 3.7%Should You Sell? - MarketBeat
Tonix Pharma says it had about $98.8M in cash and cash equivalents as of Dec 31, 2024 - MSN
Tonix reports positive results in TNX-1500 phase 1 trial - MSN
Tonix Pharmaceuticals Rises After Preliminary 2024 Results -February 07, 2025 at 03:39 pm EST - Marketscreener.com
Tonix Pharmaceuticals Recently Announced Preliminary Full Year 2024 Operating Results and Year-End Cash - GlobeNewswire
Tonix stock gains on business update, preliminary earnings report - Seeking Alpha
What's Going On With Tonix Pharmaceuticals Shares Friday? - Benzinga
Tonix Pharmaceuticals reports positive topline trial outcomes of TNX-1500 - Clinical Trials Arena
TNXP Financial Results: Strong Sales Growth & Strategic Cash Position Ahead of Critical FDA Date - StockTitan
Tonix Pharma Announces Promising Phase 1 Trial Results - TipRanks
Tonix Pharmaceuticals Announces Positive Topline Results from Phase 1 Trial for TNX-1500, a Next Generation anti-CD40L mAb Candidate for Prevention of Kidney Transplant Rejection and Treatment of Autoimmune Diseases - GlobeNewswire
Breakthrough in Transplant Medicine: Novel Anti-CD40L Antibody Achieves Key Clinical Milestones - StockTitan
Tonix Pharmaceuticals announces reverse stock split - MSN
Tonix Pharmaceuticals (NASDAQ:TNXP) Coverage Initiated by Analysts at StockNews.com - MarketBeat
Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Down 3.7%Time to Sell? - MarketBeat
TNXPTonix Pharmaceuticals Holding Corp. Latest Stock News & Market Updates - StockTitan
Tonix Pharmaceuticals to Present at BIO CEO & Investor Conference on February 10, 2025 - Nasdaq
Tonix Pharmaceuticals to Participate in the 2025 BIO CEO & Investor Conference - GlobeNewswire
Tonix's FDA Fast-Tracked Fibromyalgia Treatment Takes Center Stage at Major Investor Conference - StockTitan
Tonix Pharmaceuticals appoints new CTO amid drug development By Investing.com - Investing.com South Africa
Tonix Pharmaceuticals promotes Fogarty to CTO - MSN
Tonix Pharmaceuticals Promotes Siobhan Fogarty to Chief Technical Officer - citybiz
Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Down 7.7%Should You Sell? - MarketBeat
Tonix Pharma Promotes Fogarty to Chief Technology Officer - TipRanks
Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Craters on Stock Split before FDA Call - TipRanks
Tonix's Leadership Shakeup: New CTO to Spearhead $34M Defense Contract & Critical FDA Review - StockTitan
Tonix Pharmaceuticals (NASDAQ:TNXP) Trading 11.5% HigherWhat's Next? - MarketBeat
Why Palantir Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket - Benzinga
Tonix Pharmaceuticals (NASDAQ:TNXP) Trading Up 6.7%Should You Buy? - MarketBeat
Tonix Pharmaceuticals announces reverse stock split By Investing.com - Investing.com Canada
Tonix Pharmaceuticals Announces 1-for-100 Reverse Stock Split - GlobeNewswire
Crude Oil Moves Higher; Owens & Minor Shares Plummet - Benzinga
Dow Falls 150 Points; ISM Manufacturing PMI Rises In January - Benzinga
Tonix Pharmaceuticals Holding Corp (TNXP) 財務データ
収益
当期純利益
現金流量
EPS
0.27%
3.05%
大文字化:
|
ボリューム (24 時間):